SCHEMBL5686369

SCHEMBL5686369

COc1ccccc1C(c1cccc2ccccc12)[C@](C#N)(Cc1ccccc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
ACP3 P15309 1/20 0.38
LMNA P02545 2/20 0.37
SLC6A4 P31645 1/20 0.37
GAA P10253 1/20 0.37
EPHX2 P34913 2/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4660129 1.00 ESR1 (0.44) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4661527 0.93 ESR1 (0.41) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4661523 0.93 ESR1 (0.41) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4662668 0.93 ESR1 (0.41) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4662666 0.93 ESR1 (0.41) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4766931 0.91 ESR1 (0.42) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4722949 0.91 ESR1 (0.42) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL5686577 0.90 MAPK1 (0.45) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4660100 0.90 MAPK1 (0.45) ESR1ESR2L3MBTL1MEN1KMT2A
SCHEMBL4659905 0.90 MAPK1 (0.45) ESR1ESR2L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use WYETH 2005-01-06 US claimed
EP-1620102-A2 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS Wyeth (US) 2006-02-01 EP disclosed
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use WYETH 2005-01-06 US disclosed
WO-2004099150-A2 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS WYETH (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use HCAR2, PCCA, MCCC2 ESR1 4557/4885ESR2 1987/4885L3MBTL1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.